Astrazeneca (AZN)

 

AZN Share PerformanceMore

52 week high5,520 22/06/17
52 week low3,996 06/12/16
52 week change 219 (4.43%)
4 week volume42,364,590 21/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

AZ lung cancer drug granted priority review status

AstraZeneca and MedImmune, its global biologics research and development arm, have announced that the US Food and D...

FDA accepts sBLA file for Imfinzi; priority review

RNS Number: 7316T AstraZeneca PLC 17 October 2017 17 October 2017 07:00 BST US FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR IMFINZI IN LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER Imfinzi granted Priority Review Acceptance follows FDA's Breakthrough Therapy Designation Astra...

Broker Forecast - Credit Suisse issues a broker note on AstraZeneca PLC

Credit Suisse today upgrades its investment rating on AstraZeneca PLC (LON:AZN) to outperform (from neutral) and rai...

Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price tar...

A debt warning and short selling

If hedge funds smell blood they'll attack vulnerable companies for profit. David Brenchley reveals this fund's short positio...

Broker Forecast - HSBC issues a broker note on AstraZeneca PLC

HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4150p (f...

AZN cancer drug granted breakthrough therapy designation

AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation fo...

FDA grants Tagrisso BTD for 1st-line EGFR nsclc

RNS Number: 0020T AstraZeneca PLC 09 October 2017 9 October 2017 07:00 BST TAGRISSO GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER Designation based on positive Phase III FLAURA trial results Sixth...

Latest discussion posts More

  • EU approval in the pipeline

    The European Medicines Agency accepts for review AstraZeneca's (NYSE:AZN) marketing application seeking approval for Imfinzi (durvalumab) for the treatment of patients with ...
    9-Oct-2017
    Proverbs 26 vs 5
  • AZN cancer drug granted breakthrough therapy designation

    AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation for Tagrisso (osimertinib) for the first-line treatment of ...
    9-Oct-2017
    Proverbs 26 vs 5
  • Re: quiet

    up another 10+%
    21-Sep-2017
    nick2name

Users' HoldingsMore

Users who hold Astrazeneca also hold..
GLAXOSMITHKLINE46%
BP35%
VODAFONE GRP.35%
NATIONAL GRID35%
RDS 'B'33%

Codes & Symbols

ISINGB0009895292
SymbolsAZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN